Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Inclusion Criteria: Phase 1 Inclusion • Participant at least 18 years of age with histologically confirmed CLL/SLL or B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma \[DLBCL\], FL, mantle cell lymphoma \[MCL\], marginal zone lymphoma \[MZL\], lymphoplasmacytic lymphoma). Phase 2a Inclusion * Histological evidence: FL Grade 1-3A, with relapsed or refractory disease; aggressive NHL (aNHL), defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL) (with mycosis fungoides \[MF\]/Sézary Syndrome \[SS\]) with relapsed or refractory disease * Received B-cell receptor (BCR) and/or BCL2 inhibitors and were intolerant or had relapsed/refractory disease afterwards * Prior treatment for lymphoid malignancy for progressive /refractory disease * ≥1 prior regimen (minimum 2 cycles) with antibody conjugate/cytotoxic chemotherapy. * Measurable disease defined as: ≥1 lesion that measures ≥1.5 centimeter (cm) single dimension via computed tomography (CT), CT/positive-emission tomography (PET) with nodal or mass lesions; quantifiable circulating tumor cells; and for CTCL: Modified Severity Weighted Assessment Tool (mSWAT) \>0 * Ability to provide diagnostic reports General Inclusion * Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1 * Hematologic absolute neutrophil count (ANC) \>1000/microliter (uL) and platelet \>75,000/uL * Creatinine levels as specified by Investigat…